New Zealand markets closed

BIIB Oct 2023 190.000 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.20000.0000 (0.00%)
As of 03:20PM EDT. Market open.
Full screen
Previous close0.2000
Expiry date2023-10-20
Day's range0.2000 - 0.2000
Contract rangeN/A
Open interestN/A
  • Zacks

    Ionis (IONS) Meets Rare Disease Drug Study Goal, Stock Up 8.5%

    Ionis (IONS) reports positive phase III study results, supporting the benefits of olezarsen to treat familial chylomicronemia syndrome (FCS), a rare genetic disorder.

  • GlobeNewswire

    Biogen Completes Acquisition of Reata Pharmaceuticals

    Reata acquisition bolsters Biogen’s rare disease portfolio with the addition of SKYCLARYS® (omaveloxolone), the first and only FDA approved treatment for Friedreich’s ataxia in the U.S. CAMBRIDGE, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – has completed the acquisition of Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a company focused on developing therapeutics that regulate cellular metabolism and inflammation in serious neurologic diseases. As a result of the transact

  • Zacks

    Biogen Inc. (BIIB) Stock Sinks As Market Gains: What You Should Know

    In the latest trading session, Biogen Inc. (BIIB) closed at $255.02, marking a -1.03% move from the previous day.